Valsartan Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Valsartan Market 

5.1. COVID-19 Landscape: Valsartan Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Valsartan Market, By Product Type

8.1. Valsartan Market Revenue and Volume, by Product Type

8.1.1. Valsartan API

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Finished Dosage Forms (FDFs)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Tablets

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Fixed-dose combinations

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Valsartan Market, By Formulation

9.1. Valsartan Market Revenue and Volume, by Formulation

9.1.1. Monotherapy Formulations

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Combination Formulations

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Valsartan Market, By Dosage Strength 

10.1. Valsartan Market Revenue and Volume, by Dosage Strength

10.1.1. ≤ 80 mg

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. 81–160 mg

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. > 160 mg

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Valsartan Market, By Indication

11.1. Valsartan Market Revenue and Volume, by Indication

11.1.1. Hypertension

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Heart Failure

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Post-Myocardial Infarction

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Other Cardiovascular Conditions

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Valsartan Market, By Distribution Channel

12.1. Valsartan Market Revenue and Volume, by Distribution Channel

12.1.1. Retail Pharmacies

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Hospital Pharmacies

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Online Pharmacies

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Other Channels

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Valsartan Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Product Type

13.1.2. Market Revenue and Volume Forecast, by Formulation

13.1.3. Market Revenue and Volume Forecast, by Dosage Strength

13.1.4. Market Revenue and Volume Forecast, by Indication

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Product Type

13.1.6.2. Market Revenue and Volume Forecast, by Formulation

13.1.6.3. Market Revenue and Volume Forecast, by Dosage Strength

13.1.6.4. Market Revenue and Volume Forecast, by Indication

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Product Type

13.1.7.2. Market Revenue and Volume Forecast, by Formulation

13.1.7.3. Market Revenue and Volume Forecast, by Dosage Strength

13.1.7.4. Market Revenue and Volume Forecast, by Indication

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Product Type

13.2.2. Market Revenue and Volume Forecast, by Formulation

13.2.3. Market Revenue and Volume Forecast, by Dosage Strength

13.2.4. Market Revenue and Volume Forecast, by Indication  

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Product Type

13.2.6.2. Market Revenue and Volume Forecast, by Formulation

13.2.6.3. Market Revenue and Volume Forecast, by Dosage Strength

13.2.7. Market Revenue and Volume Forecast, by Indication  

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Product Type

13.2.9.2. Market Revenue and Volume Forecast, by Formulation

13.2.9.3. Market Revenue and Volume Forecast, by Dosage Strength

13.2.10. Market Revenue and Volume Forecast, by Indication

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Product Type

13.2.12.2. Market Revenue and Volume Forecast, by Formulation

13.2.12.3. Market Revenue and Volume Forecast, by Dosage Strength

13.2.12.4. Market Revenue and Volume Forecast, by Indication

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Product Type

13.2.14.2. Market Revenue and Volume Forecast, by Formulation

13.2.14.3. Market Revenue and Volume Forecast, by Dosage Strength

13.2.14.4. Market Revenue and Volume Forecast, by Indication

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Product Type

13.3.2. Market Revenue and Volume Forecast, by Formulation

13.3.3. Market Revenue and Volume Forecast, by Dosage Strength

13.3.4. Market Revenue and Volume Forecast, by Indication

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Product Type

13.3.6.2. Market Revenue and Volume Forecast, by Formulation

13.3.6.3. Market Revenue and Volume Forecast, by Dosage Strength

13.3.6.4. Market Revenue and Volume Forecast, by Indication

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Product Type

13.3.8.2. Market Revenue and Volume Forecast, by Formulation

13.3.8.3. Market Revenue and Volume Forecast, by Dosage Strength

13.3.8.4. Market Revenue and Volume Forecast, by Indication

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Product Type

13.3.10.2. Market Revenue and Volume Forecast, by Formulation

13.3.10.3. Market Revenue and Volume Forecast, by Dosage Strength

13.3.10.4. Market Revenue and Volume Forecast, by Indication

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Product Type

13.3.11.2. Market Revenue and Volume Forecast, by Formulation

13.3.11.3. Market Revenue and Volume Forecast, by Dosage Strength

13.3.11.4. Market Revenue and Volume Forecast, by Indication

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Product Type

13.4.2. Market Revenue and Volume Forecast, by Formulation

13.4.3. Market Revenue and Volume Forecast, by Dosage Strength

13.4.4. Market Revenue and Volume Forecast, by Indication

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Product Type

13.4.6.2. Market Revenue and Volume Forecast, by Formulation

13.4.6.3. Market Revenue and Volume Forecast, by Dosage Strength

13.4.6.4. Market Revenue and Volume Forecast, by Indication

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Product Type

13.4.8.2. Market Revenue and Volume Forecast, by Formulation

13.4.8.3. Market Revenue and Volume Forecast, by Dosage Strength

13.4.8.4. Market Revenue and Volume Forecast, by Indication

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Product Type

13.4.10.2. Market Revenue and Volume Forecast, by Formulation

13.4.10.3. Market Revenue and Volume Forecast, by Dosage Strength

13.4.10.4. Market Revenue and Volume Forecast, by Indication

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Product Type

13.4.11.2. Market Revenue and Volume Forecast, by Formulation

13.4.11.3. Market Revenue and Volume Forecast, by Dosage Strength

13.4.11.4. Market Revenue and Volume Forecast, by Indication

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Product Type

13.5.2. Market Revenue and Volume Forecast, by Formulation

13.5.3. Market Revenue and Volume Forecast, by Dosage Strength

13.5.4. Market Revenue and Volume Forecast, by Indication

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Product Type

13.5.6.2. Market Revenue and Volume Forecast, by Formulation

13.5.6.3. Market Revenue and Volume Forecast, by Dosage Strength

13.5.6.4. Market Revenue and Volume Forecast, by Indication

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Product Type

13.5.8.2. Market Revenue and Volume Forecast, by Formulation

13.5.8.3. Market Revenue and Volume Forecast, by Dosage Strength

13.5.8.4. Market Revenue and Volume Forecast, by Indication

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Alembic Pharmaceuticals Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Amneal Pharmaceuticals LLC

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Aurobindo Pharma Ltd.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Dr. Reddy's Laboratories Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Fresenius Kabi AG

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Glenmark Pharmaceuticals Ltd.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Hetero Drugs Ltd.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Hikma Pharmaceuticals PLC

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Lupin Limited

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Mylan N.V.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms